세계의 인유두종 바이러스(HPV) 백신 시장 : 동향, 예측, 경쟁 분석(-2030년)

Human Papillomavirus (HPV) Vaccine Trends and Forecast

The future of the global human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels. The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030 with a CAGR of 10.4% from 2024 to 2030. The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.

• Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.
• North America is expected to witness highest growth over the forecast period due to higher adoption of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.

Emerging Trends in the Human Papillomavirus (HPV) Vaccine Market

Emerging trends in the HPV market highlight advancements in vaccine technology, expanded vaccination coverage, and evolving public health strategies. These trends are shaping the future of HPV prevention and treatment globally.

• Expansion of Vaccine Coverage: The trend toward expanding vaccine coverage includes the development of vaccines targeting a broader range of HPV strains. This approach improves the effectiveness of vaccination programs and provides better protection against multiple HPV types, leading to more comprehensive prevention of HPV-related cancers.
• Increased Vaccination Age Limits: Increasing the age limits for HPV vaccination is a growing trend. Recent guidelines recommend extending vaccination to adults up to age 45. This trend addresses the need for prevention in older populations who may not have been previously vaccinated, enhancing overall public health outcomes.
• Integration of HPV Vaccines in Routine Immunization: Integrating HPV vaccines into routine immunization schedules is becoming more common. By including HPV vaccination as part of standard vaccination programs for adolescents, health authorities aim to increase vaccine uptake and achieve higher coverage rates, leading to greater herd immunity and reduced disease incidence.
• Focus on Male Vaccination: There is a growing focus on including males in HPV vaccination programs. Vaccinating boys as well as girls helps to reduce HPV transmission and offers protection against HPV-related cancers in men, such as oropharyngeal cancers, thus contributing to overall disease prevention.
• Public-Private Partnerships for Vaccine Access: Public-private partnerships are emerging to improve vaccine access and affordability. Collaborations between governments, NGOs, and pharmaceutical companies are facilitating the distribution of vaccines to underserved populations and developing countries, enhancing global efforts to reduce HPV-related diseases.

Emerging trends such as the expansion of vaccine coverage, increased vaccination age limits, integration into routine immunization, focus on male vaccination, and public-private partnerships are reshaping the HPV market. These trends are enhancing the effectiveness of vaccination programs, improving access, and contributing to global efforts in preventing HPV-related cancers.

Recent Developments in the Human Papillomavirus (HPV) Vaccine Market

Recent developments in the HPV market are characterized by technological advancements, regulatory updates, and enhanced public health initiatives. These developments are driving improvements in vaccine effectiveness and accessibility.

• Introduction of New HPV Vaccines: The introduction of new HPV vaccines that cover additional HPV strains represents a major development. These vaccines offer broader protection against various HPV types, improving the overall effectiveness of vaccination programs and reducing the incidence of HPV-related cancers.
• Expansion of Vaccination Programs: Recent efforts to expand HPV vaccination programs include increasing eligibility to older age groups and incorporating vaccines into routine immunization schedules. These initiatives aim to boost vaccine coverage and enhance disease prevention across different populations.
• Government Support and Funding: Increased government support and funding for HPV vaccination programs have been significant. Funding helps subsidize vaccine costs, supports public health campaigns, and facilitates the implementation of widespread vaccination efforts, leading to higher vaccination rates and improved public health outcomes.
• Inclusion of HPV Vaccines in National Health Policies: Many countries have updated their national health policies to include HPV vaccines as a standard preventive measure. This inclusion ensures that vaccines are integrated into public health strategies and that vaccination programs receive the necessary support and resources for successful implementation.
• Development of Cost-Effective Vaccines: The development and introduction of cost-effective HPV vaccines are notable. These vaccines aim to make HPV prevention more affordable, particularly in low- and middle-income countries, thus enhancing access to vaccination and contributing to global disease reduction efforts.

Recent developments such as the introduction of new HPV vaccines, expansion of vaccination programs, increased government support, inclusion in national health policies, and development of cost-effective vaccines are significantly impacting the HPV market. These advancements enhance vaccine effectiveness, accessibility, and overall public health outcomes.

Strategic Growth Opportunities for Human Papillomavirus (HPV) Vaccine Market

Strategic growth opportunities in the HPV market are driven by advancements in vaccine technology, evolving public health strategies, and increasing global demand for effective HPV prevention. These opportunities offer potential for expanding market reach and improving health outcomes.

• Expansion into Emerging Markets: Expanding HPV vaccination programs into emerging markets presents significant growth opportunities. Targeting regions with high HPV prevalence and low vaccination rates can drive market growth, improve global health outcomes, and reduce the incidence of HPV-related cancers.
• Development of Next-Generation Vaccines: Investing in the development of next-generation HPV vaccines offers growth potential. These vaccines, which provide broader protection and longer-lasting immunity, can address current limitations and meet evolving public health needs, driving market expansion and innovation.
• Integration with Digital Health Solutions: Integrating HPV vaccination programs with digital health solutions, such as mobile health apps and electronic health records, presents growth opportunities. Digital tools can enhance vaccine tracking, reminder systems, and patient education, improving vaccination rates and program effectiveness.
• Public-Private Partnerships for Global Access: Forming public-private partnerships to enhance global vaccine access is a strategic growth opportunity. Collaborations between governments, NGOs, and private companies can facilitate vaccine distribution, reduce costs, and increase accessibility in underserved regions, driving market growth and impact.
• Focus on Comprehensive Prevention Programs: Implementing comprehensive HPV prevention programs that include vaccination, screening, and public education can drive market growth. By addressing multiple aspects of HPV prevention and control, these programs enhance overall effectiveness and contribute to long-term reductions in HPV-related diseases.

Strategic growth opportunities in the HPV market include expansion into emerging markets, development of next-generation vaccines, integration with digital health solutions, public-private partnerships for global access, and focus on comprehensive prevention programs. These opportunities drive innovation, enhance accessibility, and improve global health outcomes.

Human Papillomavirus (HPV) Vaccine Market Driver and Challenges

The HPV market is influenced by various drivers and challenges, including technological advancements, economic factors, and regulatory issues. Understanding these elements is crucial for navigating the market and fostering growth.

The factors responsible for driving the human papillomavirus (hpv) vaccine market include:

1. Technological Advancements in Vaccines: Technological advancements in HPV vaccines, including the development of next-generation formulations and improved delivery methods, drive market growth. These innovations enhance vaccine efficacy and broaden protection against multiple HPV strains.

2. Increased Awareness and Education: Increased awareness and education about HPV and its related cancers boost vaccine uptake. Public health campaigns and educational initiatives help inform individuals about the benefits of vaccination, contributing to higher vaccination rates and disease prevention.

3. Government Initiatives and Funding: Government initiatives and funding support HPV vaccination programs and public health campaigns. Financial support and policy development enhance vaccine accessibility, subsidize costs, and promote widespread vaccination efforts.

4. Rising Incidence of HPV-Related Cancers: The rising incidence of HPV-related cancers, such as cervical cancer, drives demand for effective prevention measures. Increasing cancer rates highlight the need for comprehensive vaccination programs and contribute to market growth.

5. Global Health Partnerships: Global health partnerships between governments, NGOs, and private organizations facilitate vaccine distribution and access. Collaborative efforts enhance the reach of vaccination programs, especially in low- and middle-income countries, and drive market expansion.

Challenges in the human papillomavirus (hpv) vaccine market are:

1. High Vaccine Costs: High vaccine costs remain a significant challenge, particularly in low-income regions. Addressing affordability issues is essential for improving vaccine accessibility and achieving broader coverage.

2. Regulatory and Compliance Issues: Navigating complex regulatory requirements and compliance issues can be challenging. Ensuring adherence to varying regulations across regions adds complexity to vaccine development and market entry.

3. Vaccine Hesitancy: Vaccine hesitancy and misinformation can impact vaccination rates. Addressing public concerns and providing accurate information are crucial for increasing vaccine uptake and ensuring the success of vaccination programs.

Major drivers of the HPV market include technological advancements, increased awareness, government initiatives, rising cancer incidence, and global health partnerships. Key challenges include high vaccine costs, regulatory complexities, and vaccine hesitancy. Addressing these factors is crucial for market growth and improving public health outcomes.

List of Human Papillomavirus (HPV) Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies human papillomavirus (HPV) vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the human papillomavirus (HPV) vaccine companies profiled in this report include-

• Johnson & Johnson
• Xenetic Biosciences
• AstraZeneca
• Merck
• Serum Institute of India
• Inovio Pharmaceuticals
• Bharat Biotech
• Sanofi
• GlaxoSmithKline
• Novartis

Human Papillomavirus (HPV) Vaccine by Segment

The study includes a forecast for the global human papillomavirus (HPV) vaccine by type, distribution channel, and region.

Human Papillomavirus (HPV) Vaccine Market by Type [Analysis by Value from 2018 to 2030]:

• Tetravalent
• Nonavalent
• Bivalent

Human Papillomavirus (HPV) Vaccine Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

Human Papillomavirus (HPV) Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Human Papillomavirus (HPV) Vaccine Market

Recent developments in the human papillomavirus (HPV) market reflect advancements in vaccine technology, regulatory changes, and increasing global efforts to combat HPV-related diseases. Key trends and developments are observed in the United States, China, Germany, India, and Japan, each contributing to the broader goal of reducing HPV prevalence and related health issues.

• United States: In the U.S., significant progress has been made with the expansion of HPV vaccination programs. The introduction of new vaccine formulations covering a broader range of HPV strains has improved effectiveness. Enhanced public health campaigns and expanded eligibility for vaccination, including adults up to age 45, are driving increased vaccine uptake and contributing to reductions in HPV-related cancers.
• China: China has made substantial strides in HPV vaccination with increased government support for vaccination programs and subsidies. Recent developments include the approval of domestic HPV vaccines and widespread vaccination campaigns targeting school-age children. These efforts aim to curb the high incidence of cervical cancer and improve public health outcomes.
• Germany: Germany has seen advancements in HPV vaccination with a focus on broadening vaccine coverage and improving access. Recent initiatives include updated vaccination guidelines recommending broader age groups and the inclusion of boys in vaccination programs. These measures are expected to enhance herd immunity and further reduce HPV-related disease incidence.
• India: In India, recent developments include the launch of cost-effective HPV vaccines and expanded vaccination initiatives targeting rural and underserved populations. Government and non-governmental organizations are working together to increase vaccine accessibility and awareness, aiming to reduce the high incidence of cervical cancer in the country.
• Japan: Japan has advanced its HPV vaccination strategy with new vaccine approvals and public health initiatives. Recent developments include updated vaccination recommendations to cover a wider range of HPV types and increased funding for vaccination programs. These efforts are designed to enhance vaccination rates and prevent HPV-related diseases more effectively.

Features of the Global Human Papillomavirus (HPV) Vaccine Market

Market Size Estimates: Human papillomavirus (HPV) vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Human papillomavirus (HPV) vaccine market size by type, distribution channel, and region in terms of value ($B).

Regional Analysis: Human papillomavirus (HPV) vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, distribution channels, and regions for the human papillomavirus (HPV) vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the human papillomavirus (HPV) vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the human papillomavirus (HPV) vaccine market size?

Answer: The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030.

Q.2 What is the growth forecast for human papillomavirus (HPV) vaccine market?

Answer: The global human papillomavirus (HPV) vaccine market is expected to grow with a CAGR of 10.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the human papillomavirus (HPV) vaccine market?

Answer: The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.

Q4. What are the major segments for human papillomavirus (HPV) vaccine market?

Answer: The future of the human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels.

Q5. Who are the key human papillomavirus (HPV) vaccine market companies?

Answer: Some of the key human papillomavirus (HPV) vaccine companies are as follows:

• Johnson & Johnson
• Xenetic Biosciences
• AstraZeneca
• Merck
• Serum Institute of India
• Inovio Pharmaceuticals
• Bharat Biotech
• Sanofi
• GlaxoSmithKline
• Novartis

Q6. Which human papillomavirus (HPV) vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.

Q7. In human papillomavirus (HPV) vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to higher adoption of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the human papillomavirus (HPV) vaccine market by type (tetravalent, nonavalent, and bivalent), distribution channel (hospital & retail pharmacies, government suppliers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Human Papillomavirus (HPV) Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Human Papillomavirus (HPV) Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Human Papillomavirus (HPV) Vaccine Market by Type
  • 3.3.1: Tetravalent
  • 3.3.2: Nonavalent
  • 3.3.3: Bivalent
• 3.4: Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
  • 3.4.1: Hospital & Retail Pharmacies
  • 3.4.2: Government Suppliers
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Human Papillomavirus (HPV) Vaccine Market by Region
• 4.2: North American Human Papillomavirus (HPV) Vaccine Market
  • 4.2.1: North American Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent 4.2.2: North American Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
• 4.3: European Human Papillomavirus (HPV) Vaccine Market
  • 4.3.1: European Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
  • 4.3.2: European Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
• 4.4: APAC Human Papillomavirus (HPV) Vaccine Market
  • 4.4.1: APAC Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
  • 4.4.2: APAC Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
• 4.5: ROW Human Papillomavirus (HPV) Vaccine Market
  • 4.5.1: ROW Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
  • 4.5.2: ROW Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Type
  • 6.1.2: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Region
• 6.2: Emerging Trends in the Global Human Papillomavirus (HPV) Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Human Papillomavirus (HPV) Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Human Papillomavirus (HPV) Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Johnson & Johnson
• 7.2: Xenetic Biosciences
• 7.3: AstraZeneca
• 7.4: Merck
• 7.5: Serum Institute of India
• 7.6: Inovio Pharmaceuticals
• 7.7: Bharat Biotech
• 7.8: Sanofi
• 7.9: GlaxoSmithKline
• 7.10: Novartis